Lyra Therapeutics Advances in CRS Treatment Amid Market Volatility
Lyra Therapeutics, a clinical-stage biotech company, is focused on developing innovative treatments for chronic rhinosinusitis, with its stock currently valued at $10.7 million.
2 minutes to read